Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis (IPHC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00454519 |
Recruitment Status : Unknown
Verified February 2009 by Wuhan University.
Recruitment status was: Recruiting
First Posted : March 30, 2007
Last Update Posted : February 13, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
OBJECTIVES:
- Determine response and survival of patients with peritoneal carcinomatosis treated with cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
- Assess the quality of life of patients treated with this regimen.
OUTLINE: Patients are randomized into IPHC group and control group. In the former group, the patients undergo cytoreductive surgery plus intraoperative hyperthermic peritoneal perfusion with cisplatin and mitomycin over 60 minutes. Patients in the control group just underwent routine cytoreductive surgery.
All patients in both groups receive the standard conventional chemotherapy after surgery.
Quality of life is assessed at study initiation, at 1, 3, 6 months. Patients are followed at 4 weeks, every 3 months for 1 year, and then every 6 months for up to 3 years.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stomach Neoplasms Colorectal Neoplasms Neoplasm Metastasis Mesothelioma | Procedure: cytoreductive surgery Procedure: intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin | Phase 2 |
DISEASE CHARACTERISTICS:
- Histologically confirmed peritoneal carcinomatosis with the following histologies:
- Primary peritoneal mesothelioma
- Adenocarcinoma of gastrointestinal tract origin
- Confined to peritoneal cavity
- Tumor mass could be debulked to less than 2.5 cm in diameter per tumor deposit
- Must not have failed prior intraperitoneal platinum therapy
- Treatment failure is defined as radiographic evidence of disease progression on 2 consecutive CT scans within 3 months after therapy
PATIENT CHARACTERISTICS:
Age:
- 20 to 70 years old
Performance status:
- KPS>50
Life expectancy:
- More than 8 weeks
Hematopoietic:
- WBC at least 3,500/mm^3
- Platelet count at least 80,000/mm^3
Hepatic:
- Bilirubin no greater than 2 times upper limit of normal (ULN)
- AST and ALT no greater than 2 times ULN
- Liver enzymes no greater than 2 times ULN
Renal:
- Creatinine no greater than 1.5 mg/dL
Cardiovascular:
- No significant irreversible cardiac ischemia
- No significant changes in ECG recording
Pulmonary:
- FEV_1 at least 1.2 liters
- Maximum voluntary ventilation at least 50% expected
Other:
- Not pregnant or nursing
- Negative pregnancy test
- No concurrent medical problems that would preclude surgery
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial |
Study Start Date : | March 2007 |
Estimated Primary Completion Date : | December 2009 |
Arm | Intervention/treatment |
---|---|
Experimental: A
cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
|
Procedure: intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
Other Name: HIPEC |
Active Comparator: B
cytoreductive surgery alone, postoperative chemotherapy.
|
Procedure: cytoreductive surgery
the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible. |
- overall survival time [ Time Frame: from operation to death due to cancer recurrence ]
- perioperative morbidity and mortality [ Time Frame: Within 30 days postoperation ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Gastric cancer or colorectal cancer with peritoneal carcinomatosis
- Gastric cancer or colorectal cancer with malignant ascites
- Karnofsky Performance Scale(KPS)>50
Exclusion Criteria:
- Age less than 20 years old, or beyond 70 years old
- Any lung metastasis, liver metastasis, or prominent retroperitoneal lymph node metastasis
- Bilirubin greater than 3 times upper limit of normal (ULN)
- AST and ALT greater than 5 times ULN
- Liver enzymes greater than 3 times ULN

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00454519
Contact: Yan Li, M.D., Ph.D | +86-27-62337478 | liyansd2@163.com |
China, Hubei | |
Cancer Center of Wuhan University & Department of Oncology, Zhongnan Hospital of Wuhan University | Recruiting |
Wuhan, Hubei, China, 430071 | |
Contact: Yan Li, M.D., Ph.D +86-27-67813152 ext 3152 liyansd2@163.com | |
Contact: Yonemura Yutaka, M.D., Ph.D +81-072-433-2131 y.yonemura@coda.ocn.ne.jp | |
Sub-Investigator: Guo-Liang Yang, M.D | |
Sub-Investigator: Fu-Lin Cheng, M.D. | |
Principal Investigator: Yan Li, M.D., Ph.D | |
Sub-Investigator: Mao-Hui Feng, M.D., Ph.D | |
Sub-Investigator: Shibo Masaya, M.D. |
Principal Investigator: | Yan Li, M.D., Ph.D | Cancer Center of Wuhan University | |
Principal Investigator: | Yonemura Yutaka, MD, PhD | NPO Organization to Support Peritoneal Dissemination Treatment |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Prof. Yan Li, M.D., Ph.D, Cancer Center of Wuhan University |
ClinicalTrials.gov Identifier: | NCT00454519 |
Other Study ID Numbers: |
WUCC-0701 |
First Posted: | March 30, 2007 Key Record Dates |
Last Update Posted: | February 13, 2009 |
Last Verified: | February 2009 |
peritoneal carcinomatosis cisplatin mitomycin gastric cancer colorectal cancer |
Neoplasms Neoplasm Metastasis Mesothelioma Colorectal Neoplasms Carcinoma Peritoneal Neoplasms Stomach Neoplasms Neoplastic Processes Pathologic Processes Adenoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms, Mesothelial Neoplasms by Site Intestinal Neoplasms |
Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Abdominal Neoplasms Peritoneal Diseases Stomach Diseases Cisplatin Mitomycins Mitomycin Antineoplastic Agents Antibiotics, Antineoplastic |